# Aardvark Therapeutics Inc. (AARD)

Source: https://www.quantisnow.com/company/AARD
Generated: 2026-11-12T01:59:13.405Z

- Ticker: AARD
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2025
- SEC CIK: 0001774857

## Latest AARD news and filings

- 2026-11-10 22:18 UTC [SEC Form 4] [Chief Executive Officer Lee Tien-Li was granted 793,951 stock options and returned 793,951 stock options to the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-lee-tien-li-was-granted-793951-stock-options-6784706)
- 2026-11-10 22:13 UTC [SEC Form 4] [Officer Sun Nelson was granted 304,094 stock options and returned 304,094 stock options to the company (SEC Form 4)](https://www.quantisnow.com/insight/officer-sun-nelson-was-granted-304094-stock-options-and-returned-6784673)
- 2026-11-10 22:09 UTC [SEC Form 4] [Chief Medical Officer Jaiman Manasi was granted 374,560 stock options and returned 374,560 stock options to the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-jaiman-manasi-was-granted-374560-stock-options-6784645)
- 2026-11-05 11:45 UTC [Analyst Downgrade] [Aardvark Therapeutics downgraded by Raymond James](https://www.quantisnow.com/insight/aardvark-therapeutics-downgraded-by-raymond-james-6774294)
- 2026-10-23 12:38 UTC [SEC Form 8-K] [SEC Form 8-K filed by Aardvark Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-aardvark-therapeutics-inc-6755942)
- 2026-10-23 11:00 UTC [Earnings Date] [Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials](https://www.quantisnow.com/insight/aardvark-therapeutics-reports-exploratory-data-from-the-terminated-hero-and-6755775)
- 2026-10-22 20:17 UTC [SEC Form 8-K] [SEC Form 8-K filed by Aardvark Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-aardvark-therapeutics-inc-6755258)
- 2026-10-22 20:05 UTC [Earnings Date] [Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data](https://www.quantisnow.com/insight/aardvark-therapeutics-announces-fda-has-lifted-the-clinical-hold-on-6754997)
- 2026-10-09 14:20 UTC [Market Insight] [AARD UPCOMING DEADLINE: Levi & Korsinsky Alerts Aardvark Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm](https://www.quantisnow.com/insight/aard-upcoming-deadline-levi-korsinsky-alerts-aardvark-therapeutics-inc-stockholders-6742606)
- 2026-10-08 20:49 UTC [SEC Form 4] [SEC Form 4 filed by Aardvark Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-aardvark-therapeutics-inc-6741991)
- 2026-10-08 20:47 UTC [SEC Form 3] [SEC Form 3 filed by Aardvark Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-3-filed-by-aardvark-therapeutics-inc-6741984)
- 2026-10-08 20:14 UTC [SEC Form 8-K] [SEC Form 8-K filed by Aardvark Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-aardvark-therapeutics-inc-6741839)
- 2026-10-08 12:00 UTC [Public Offering] [Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors](https://www.quantisnow.com/insight/aardvark-therapeutics-appoints-clinical-development-leader-david-zhang-phd-mba-6741093)
- 2026-10-02 20:05 UTC [Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/aardvark-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-6734292)
- 2026-09-12 00:14 UTC [SEC Form 4] [Officer Sun Nelson sold $394,957 worth of shares (76,754 units at $5.15) as part of a pre-agreed trading plan, decreasing direct ownership by 68% to 35,475 units (SEC Form 4)](https://www.quantisnow.com/insight/officer-sun-nelson-sold-394957-worth-of-shares-76754-units-6713461)
- 2026-08-21 23:48 UTC [SEC Form 4] [SEC Form 4 filed by Director Chi Jeffrey](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-chi-jeffrey-6691863)
- 2026-08-21 23:46 UTC [SEC Form 4] [SEC Form 4 filed by Director Graf Susan E](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-graf-susan-e-6691862)
- 2026-08-21 23:45 UTC [SEC Form 4] [SEC Form 4 filed by Director Baynes Roy D.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-baynes-roy-d-6691861)
- 2026-08-21 23:45 UTC [SEC Form 4] [SEC Form 4 filed by Director Tong Victor Edward Jr](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-tong-victor-edward-jr-6691860)
- 2026-08-17 20:10 UTC [SEC Form 8-K] [Aardvark Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/aardvark-therapeutics-inc-filed-sec-form-8-k-submission-of-matters-6684976)
- 2026-08-11 21:09 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Aardvark Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-aardvark-therapeutics-inc-6676412)
- 2026-08-11 21:05 UTC [SEC Form 8-K] [Aardvark Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/aardvark-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6676391)
- 2026-08-11 20:53 UTC [Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates](https://www.quantisnow.com/insight/aardvark-therapeutics-reports-second-quarter-2026-financial-results-and-provides-6676327)
- 2026-07-10 20:05 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Aardvark Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-aardvark-therapeutics-inc-6634082)
- 2026-06-29 20:05 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Aardvark Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-aardvark-therapeutics-inc-6618912)
- 2026-06-12 20:05 UTC [SEC Form 8-K] [Aardvark Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/aardvark-therapeutics-inc-filed-sec-form-8-k-leadership-update-financial-6600155)
- 2026-05-15 12:24 UTC [Analyst Downgrade] [Aardvark Therapeutics downgraded by Morgan Stanley with a new price target](https://www.quantisnow.com/insight/aardvark-therapeutics-downgraded-by-morgan-stanley-with-a-new-price-6555893)
- 2026-05-14 20:15 UTC [SEC Form 8-K] [Aardvark Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/aardvark-therapeutics-inc-filed-sec-form-8-k-other-events-financial-6554109)
- 2026-05-14 20:01 UTC [Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold](https://www.quantisnow.com/insight/aardvark-therapeutics-plans-to-unblind-hero-and-ole-data-to-6553504)
- 2026-05-07 13:32 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Aardvark Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-aardvark-therapeutics-inc-6538030)
- 2026-05-07 13:28 UTC [SEC Form 8-K] [Aardvark Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/aardvark-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6538020)
- 2026-05-07 12:00 UTC [Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates](https://www.quantisnow.com/insight/aardvark-therapeutics-reports-first-quarter-2026-financial-results-and-provides-6537608)
- 2026-04-06 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Aardvark Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-aardvark-therapeutics-inc-6488514)
- 2026-04-03 20:05 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Aardvark Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-aardvark-therapeutics-inc-6487368)
- 2026-03-23 21:10 UTC [SEC Form S-3] [SEC Form S-3 filed by Aardvark Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-aardvark-therapeutics-inc-6465512)
- 2026-03-23 20:19 UTC [SEC Form 10-K] [SEC Form 10-K filed by Aardvark Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-aardvark-therapeutics-inc-6465195)
- 2026-03-23 20:09 UTC [SEC Form 8-K] [Aardvark Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/aardvark-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6465052)
- 2026-03-23 20:05 UTC [Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates](https://www.quantisnow.com/insight/aardvark-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-6464952)
- 2026-03-02 13:53 UTC [Analyst Downgrade] [Aardvark Therapeutics downgraded by Stifel with a new price target](https://www.quantisnow.com/insight/aardvark-therapeutics-downgraded-by-stifel-with-a-new-price-target-6421052)
- 2026-03-02 13:52 UTC [Analyst Downgrade] [Aardvark Therapeutics downgraded by Morgan Stanley with a new price target](https://www.quantisnow.com/insight/aardvark-therapeutics-downgraded-by-morgan-stanley-with-a-new-price-6421048)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/AARD
- Earnings history: https://www.quantisnow.com/earnings/AARD
- Dividend history: https://www.quantisnow.com/dividends/AARD
- Insider transactions: https://www.quantisnow.com/insiders/AARD
- Options chain: https://www.quantisnow.com/options/AARD
- SEC 8-K filings only: https://www.quantisnow.com/company/AARD/8-k
- RSS and alerts for AARD: https://www.quantisnow.com/docs/rss-feeds.md